Evidence map›Paper›PMID 36148304›Full record

ArticleFrontiers in physiology2022

Production of recombinant human xCT (SLC7A11) and reconstitution in proteoliposomes for functional studies.

Michele Galluccio, Mariafrancesca Scalise, Gilda Pappacoda, Martina Scarpelli, Marcella Bonanomi, Daniela Gaglio, Cesare Indiveri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Over-Production of the Human SLC7A10 inInternational journal of molecular sciences · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Michele GalluccioUnit of Biochemistry and Molecular Biotechnology, Department DiBEST (Biologia Ecologia Scienze della Terra), University of Calabria, Arcavacata di Rende, Italy.
Mariafrancesca ScaliseUnit of Biochemistry and Molecular Biotechnology, Department DiBEST (Biologia Ecologia Scienze della Terra), University of Calabria, Arcavacata di Rende, Italy.
Gilda PappacodaUnit of Biochemistry and Molecular Biotechnology, Department DiBEST (Biologia Ecologia Scienze della Terra), University of Calabria, Arcavacata di Rende, Italy.
Martina ScarpelliUnit of Biochemistry and Molecular Biotechnology, Department DiBEST (Biologia Ecologia Scienze della Terra), University of Calabria, Arcavacata di Rende, Italy.
Marcella BonanomiDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.
Daniela GaglioISBE.IT/Centre of Systems Biology, Milan, Italy.
Cesare IndiveriUnit of Biochemistry and Molecular Biotechnology, Department DiBEST (Biologia Ecologia Scienze della Terra), University of Calabria, Arcavacata di Rende, Italy.
University of Calabria · ITInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies · ITNational Research Council · ITUniversity of Milano-Bicocca · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The plasma membrane transporter xCT belongs to the SLC7 family and has the physiological role of mediating the exchange of glutamate and cystine across the cell plasma membrane, being crucial for redox control. The xCT protein forms a heterodimer with the ancillary protein CD98. Over the years, xCT became a hot pharmacological target due to the documented over-expression in virtually all human cancers, which rely on cystine availability for their progression. Notwithstanding, several unknown aspects of xCT biology still exist that require a suitable single protein experimental model, to be addressed. To this aim, the recombinant host

Indexed as

cystineglutamateliposomesover-expressionreactive oxygen speciesredox controlSLC7A11xCT

Identifiers

PMID36148304
PMCPMC9485625
OpenAlexW4294752651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.